Genmab A/S (GNMSF) Operating Expenses (2018 - 2026)
Genmab A's (GNMSF) quarterly Operating Expenses came in at -$716.0 million in Q1 2026, down 35.86% YoY from -$1.1 billion in Q1 2025, and up 56.74% on a QoQ basis from -$1.7 billion in Q3 2025.
Genmab A/S (GNMSF) Operating Expenses (2018 - 2026) Analysis & Trends
Genmab A (GNMSF) has 8 years of Operating Expenses data on file, last reported at -$716.0 million in Q1 2026.
- Quarterly Operating Expenses fell 35.86% year-over-year to -$716.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.5 billion (down 11.96% YoY) and the FY2025 annual result came in at $2.7 billion, up 23.55% from the prior year.
- Operating Expenses advanced to -$716.0 million in Q1 2026, from -$1.7 billion in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $2.0 billion in Q4 2023 to a low of -$1.7 billion in Q3 2025.
- A 4-year average of -$627.8 million and a median of -$873.0 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2025 — Operating Expenses slipped 6.02% — and 2026, when it plunged 35.86%.
- Tracing GNMSF's Operating Expenses over 4 years: stood at $2.0 billion in 2023, then tumbled by 176.0% to -$1.5 billion in 2024, then fell by 7.75% to -$1.7 billion in 2025, then surged by 56.74% to -$716.0 million in 2026.
- The last three Operating Expenses figures came in at -$716.0 million (Q1 2026), -$1.7 billion (Q3 2025), and -$1.1 billion (Q2 2025), per Business Quant data.
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 780.00 Mn |
| Mar 31, 2026 | -716.00 Mn |
| Sep 30, 2025 | -1.66 Bn |
| Jun 30, 2025 | -1.09 Bn |
| Mar 31, 2025 | -527.00 Mn |
| Sep 30, 2024 | -1.54 Bn |
| Jun 30, 2024 | -1.03 Bn |
| Mar 31, 2024 | -487.00 Mn |
| Dec 31, 2023 | 2.02 Bn |
| Mar 31, 2021 | -76.00 Mn |
| Sep 30, 2020 | -866.00 |
| Mar 31, 2020 | -2.00 Mn |
| Dec 31, 2019 | -689.00 |
| Sep 30, 2019 | -689.11 Mn |
| Dec 31, 2018 | -398.42 Mn |